Skip to content
10-Q

Quarterly Report

Karyopharm Therapeutics Inc. KPTI

0001193125-26-222827

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 22.66M sh
Shares Diluted Q1 2026 · Mar 31, 2026 24.72K sh
Shares Diluted Q1 2026 · Mar 31, 2025 8.47K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$22.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$38.98M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $90.85M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $60.54M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $38.78M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$265.65M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$292.93M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$205.88M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$186.02M
Current Liabilities Q1 2026 · Mar 31, 2026 $117.3M
Current Liabilities Q1 2026 · Dec 31, 2025 $92.06M
Total Liabilities Q1 2026 · Mar 31, 2026 $397.06M
Total Liabilities Q1 2026 · Dec 31, 2025 $401.34M
Current Assets Q1 2026 · Mar 31, 2026 $126.33M
Current Assets Q1 2026 · Dec 31, 2025 $103.15M
Total Assets Q1 2026 · Mar 31, 2026 $131.42M
Total Assets Q1 2026 · Dec 31, 2025 $108.42M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.24
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.77
Eps Basic Q1 2026 · Mar 31, 2026 −$1.02
Eps Basic Q1 2026 · Mar 31, 2025 −$2.77
Sga Expense Q1 2026 · Mar 31, 2026 $26.68M
Sga Expense Q1 2026 · Mar 31, 2025 $27.35M
Rd Expense Q1 2026 · Mar 31, 2026 $33.8M
Rd Expense Q1 2026 · Mar 31, 2025 $34.62M
Net Income Q1 2026 · Mar 31, 2026 −$22.39M
Net Income Q1 2026 · Mar 31, 2025 −$23.46M
Operating Income Q1 2026 · Mar 31, 2026 −$26.76M
Operating Income Q1 2026 · Mar 31, 2025 −$33.26M
Revenue Q1 2026 · Mar 31, 2026 $35.07M
Revenue Q1 2026 · Mar 31, 2025 $30.02M